An open-label extension study to evaluate the long-term safety and tolerability of bifeprunox in the treatment of outpatients with schizophrenia
Phase of Trial: Phase III
Latest Information Update: 26 Dec 2007
At a glance
- Drugs Bifeprunox (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Wyeth
- 26 Dec 2007 Status changed from recruiting to completed.
- 02 Dec 2006 New trial record.